20.500.12556/DiRROS-27796 Response rate of the third and fourth doses of the BNT162b2 vaccine administered to cancer patients undergoing active anti-neoplastic treatments SARS-CoV-2 BNT162b2 vaccine cancer patients anti-neoplastic treatment chemotherapy antibodies immunogenicity COVID-19 immunocompromise farmakologija covid-19 cepivo BNT162b2 onkološki bolniki zdravljenje novotvorb kemoterapija protitelesa imunogenost oslabljena imunost true false true MDPI AG, 2013- Diseases Angleški jezik Slovenski jezik © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Neznano 2026-02-25 09:27:44 2026-02-25 09:27:44 2026-02-26 03:55:12 0000-00-00 00:00:00 2023 0 0 Soavtorica iz Slovenije: Urška Janžič ; str. 1-13 iss. 4 Vol.ǂ 11 2023 0000-00-00 Zaloznikova Objavljeno apc 2023-08-22 2023-09-25 2023-09-26 615 2079-9721 10.3390/diseases11040128 168100867 https://www.mdpi.com/2079-9721/11/4/128 1 dcfcffba-1223-11f1-9cb0-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=40865 RAZ_Agbarya_Abed_2023.pdf RAZ_Agbarya_Abed_2023.pdf 1 443EEA9A577E71997CE49BED916EE288 5e895895043b038057b7dc44213551ab029367bb55ce827cb9c0d4436881be47 3ca0b6fe-1224-11f1-9cb0-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=40866 Univerzitetna klinika za pljučne bolezni in alergijo Golnik 0 0 0